Abstract
Major depression is common, often severe, and usually recurrent, and it carries an excess risk of mortality due to medical illness as well as suicide. At referral centers, recurrence risk averages 85% within 2–3 years of full recovery from an acute episode. The natural history of major depression is highly variable, but typically episodes last ca. 6 months, with cycles of ca. 2 years. Yet, most long-term treatment studies are limited to the year or two following recovery from an acute episode. Accordingly, available evidence best supports a relapse-preventing effect of tricyclic antidepressants or lithium within the first months after apparent recovery but is less compelling regarding prevention of later recurrences of new episodes. Other treatments have not been evaluated systematically. The hypothesis that bipolarlike, but apparently unipolar, patients might respond selectively to lithium maintenance requires further testing. Knowledge of long- term dose-benefit and dose-risk relationships is starting to emerge for lithium, but these relationships remain inadequately tested for antidepressants. Actual levels of clinical treatment of major depression appear to fall short of the ideal, and much additional research and education is required to improve care in this very common disorder.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Akiskal HS (1978) Diagnosis and classification of affective disorders: new insights from clinical and laboratory approaches. Psychiatr Dev 2: 123–160
Angst J, Weis P, Grof P, Baastrup PC, Schou M (1970) Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 116: 604–614
Avery D, Winokur G (1976) Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 33: 1029–1037
Baastrup PC, Schou M (1967) Lithium as a prophylactic agent. Its effectiveness against recurrent depressions and manic depressive psychosis. Arch Gen Psychiatry 16: 162–172
Baldessarini RJ (1983) Biomedical aspects of depression and its treatment. American Psychiatric Press, Washington
Baldessarini RJ (1985) Chemotherapy in psychiatry: principles and practice. Harvard University Press, Cambridge
Cohen BM, Baldessarini RJ (1985) Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 142: 489–492
Coppen A, Peet M (1979) The long-term management of patients with affective disorders. In: Paykel ES, Coppen A (eds) Psychopharmacology of affective disorders. Oxford University Press, New York, pp 248–256
Coryell W, Andreasen NC, Endicott J, Keller M (1987) The significance of past mania or hypomania in the course and outcome of major depression. Am J Psychiatry 144: 309–315
Davis JM (1976) Overview: Maintenance therapy in psychiatry. II. Affective disorders. Am J Psychiatry 133: 1–13
Dunner DL, Stallone F, Fieve RR (1982) Prophylaxis with lithium carbonate: an update. Arch Gen Psychiatry 39: 1344–1345
Frankenburg F, Tohen M, Cohen BM, Lipinski JF (1988) Long-term response to carbamazepine: a retrospective study. J Clin Psychopharmacol 8: 130–132
Grof P, Angst J, Haines T (1974) The clinical course of depression: practical issues. In: Angst J (ed) Classification and prediction of outcome in depression. Springer, Berlin Heidelberg New York, pp 141–147
Grof P, Hux M, Grof E, Arato M (1983) Prediction of response to stabilizing lithium treatment. Pharmacopsychiatry 16: 195–200
Hartigan GP (1963) The use of lithium salts in affective disorders. Br J Psychiatry 109: 810–814
Keller MB, Klerman GL, Lavori PW, Fawcett J A, Coryell W, Endicott J (1982) Treatment received by depressed patients. JAMA 248: 1848–1855
Keller MB, Lavori PW, Klerman GL, Andreasen NC, Endicott J, Coryell W, Fawcett J, Rice JP, Hirschfeld RMA (1986) Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 43: 458–466
Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykel ES (1974) Treatment of depression by drugs and psychotherapy. Am J Psychiatry 131: 186–191
Maj M, Starace F, Nolfe G, Kemali D (1986) Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry 19: 420–423
Mendlewicz J, Fieve R, Stallone F (1973) Relationship between effectiveness of lithium therapy and family history. Am J Psychiatry 130: 1011–1013
Murphy GE, Woodruff RA, Herjanic M, Super G (1974) Variability of the clinical course of primary affective disorder. Arch Gen Psychiatry 30: 757–761
Placidi GF, Lenzi A, Lazzerini F, Cassano G, Akiskal HS (1986) The comparative efficacy and safety of carbamazepine vs. lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 47: 490–494
Prien RF (1983) Long-term maintenance therapy in affective disorders. In: Rifkin A (ed) Schizophrenia and affective disorders: biology and drug treatment. Wright-PSG, Littleton, MA pp 95–115
Prien RF, Caffey EM Jr (1976) Relationship between dosage and response to lithium prophylaxis in recurrent depression. Am J Psychiatry 133: 567–570
Prien RF, Kupfer DJ (1986) Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 143: 18–23
Risse SC, Beitman BD, Brinkley JR (1985) Evaluation of long-term of antidepressant medication. Hosp Community Psychiatry 36: 1215–1216
Schou M (1979) Lithium as a prophylactic agent in unipolar affective illness: comparison with cyclic antidepressants. Arch Gen Psychiatry 36: 849–851
Stein MK, Rickels K, Weiss CC (1980) Maintenance therapy with amitriptyline: a controlled trial. Am J Psychiatry 137: 370–371
World Health Organization (WHO) Collaborative Study Group (1986) Dose effects of antidepressant medication in different populations. J Affect Dis 2 [Suppl]: Sl–S67
Zis AP, Goodwin FK (1979) Major affective disorder as a recurrent illness: a critical review. Arch Gen Psychiatry 36: 835–839
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Baldessarini, R.J., Tohen, M. (1988). Is There a Long-Term Protective Effect of Mood-Altering Agents in Unipolar Depressive Disorder?. In: Casey, D.E., Christensen, A.V. (eds) Psychopharmacology: Current Trends. Psychopharmacology Series, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73280-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-73280-5_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73282-9
Online ISBN: 978-3-642-73280-5
eBook Packages: Springer Book Archive